<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02141763</url>
  </required_header>
  <id_info>
    <org_study_id>PA0007</org_study_id>
    <secondary_id>2013-004949-16</secondary_id>
    <nct_id>NCT02141763</nct_id>
  </id_info>
  <brief_title>Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis</brief_title>
  <official_title>A Subject-blind, Investigator-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of UCB4940 in Subjects With Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Celltech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>MAC Clinical Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>COMAC, Bulgaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ARENSIA, Moldova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of UCB4940 in subjects with psoriatic arthritis to evaluate the safety and body
      distribution of UCB4940 in those patients. Neither the patient nor the doctor will know the
      treatment group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration at steady state (CmaxSS) of UCB 4940 during the duration of the study (up to Day 141)</measure>
    <time_frame>From Baseline to Day 141</time_frame>
    <description>Day 1: predose; 1 hour (hr), 1.5 hr, 5 hr, 12 hr, 24 hr postdose
Day 8, 15: 1 sample
Day 22: predose, 1 hr postdose
Day 43: predose; 1 hr, 1.5 hr, 5 hr, 12 hr, 24 hr postdose
Day 48, 57, 64, 85, 141: 1 sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum plasma concentration at steady state (CminSS) of UCB4940 during the duration of the study (up to Day 141)</measure>
    <time_frame>From Baseline to Day 141</time_frame>
    <description>Day 1: predose; 1 hour (hr), 1.5 hr, 5 hr, 12 hr, 24 hr postdose
Day 8, 15: 1 sample
Day 22: predose, 1 hr postdose
Day 43: predose; 1 hr, 1.5 hr, 5 hr, 12 hr, 24 hr postdose
Day 48, 57, 64, 85, 141: 1 sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve at steady state (AUCtau) of UCB4940 during the duration of the study (up to Day 141)</measure>
    <time_frame>From Baseline to Day 141</time_frame>
    <description>Day 1: predose; 1 hour (hr), 1.5 hr, 5 hr, 12 hr, 24 hr postdose
Day 8, 15: 1 sample
Day 22: predose, 1 hr postdose
Day 43: predose; 1 hr, 1.5 hr, 5 hr, 12 hr, 24 hr postdose
Day 48, 57, 64, 85, 141: 1 sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration at steady state (tmax) of UCB4940 during the duration of the study (up to Day 141)</measure>
    <time_frame>From Baseline to Day 141</time_frame>
    <description>Day 1: predose; 1 hour (hr), 1.5 hr, 5 hr, 12 hr, 24 hr postdose
Day 8, 15: 1 sample
Day 22: predose, 1 hr postdose
Day 43: predose; 1 hr, 1.5 hr, 5 hr, 12 hr, 24 hr postdose
Day 48, 57, 64, 85, 141: 1 sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Clearance (CL) of UCB4940 during the duration of the study (up to Day 141)</measure>
    <time_frame>From Baseline to Day 141</time_frame>
    <description>Day 1: predose; 1 hour (hr), 1.5 hr, 5 hr, 12 hr, 24 hr postdose
Day 8, 15: 1 sample
Day 22: predose, 1 hr postdose
Day 43: predose; 1 hr, 1.5 hr, 5 hr, 12 hr, 24 hr postdose
Day 48, 57, 64, 85, 141: 1 sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (V) of UCB4940 during the duration of the study (up to Day 141)</measure>
    <time_frame>From Baseline to Day 141</time_frame>
    <description>Day 1: predose; 1 hour (hr), 1.5 hr, 5 hr, 12 hr, 24 hr postdose
Day 8, 15: 1 sample
Day 22: predose, 1 hr postdose
Day 43: predose; 1 hr, 1.5 hr, 5 hr, 12 hr, 24 hr postdose
Day 48, 57, 64, 85, 141: 1 sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with at least one Treatment Emergent Adverse Event (TEAE) during the study</measure>
    <time_frame>From Baseline to Day 141</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>240/160/160 mg of UCB4940</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>240 mg loading dose + 160 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>160/80/80 mg of UCB4940</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>160 mg loading dose + 80 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80/40/40 mg of UCB4940</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg loading dose + 40 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>560/320/320 mg of UCB4940</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>560 mg loading dose + 320 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride aqueous solution (physiological saline, preservative free) of pharmacopoeia (USP/Ph.Eur) quality in a 10 mL glass vial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UCB4940 40 mg</intervention_name>
    <description>Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous</description>
    <arm_group_label>80/40/40 mg of UCB4940</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UCB4940 80 mg</intervention_name>
    <description>Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous</description>
    <arm_group_label>160/80/80 mg of UCB4940</arm_group_label>
    <arm_group_label>80/40/40 mg of UCB4940</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UCB4940 160 mg</intervention_name>
    <description>Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous</description>
    <arm_group_label>240/160/160 mg of UCB4940</arm_group_label>
    <arm_group_label>160/80/80 mg of UCB4940</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UCB4940 240 mg</intervention_name>
    <description>Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous</description>
    <arm_group_label>240/160/160 mg of UCB4940</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UCB4940 320 mg</intervention_name>
    <description>Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous</description>
    <arm_group_label>560/320/320 mg of UCB4940</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UCB4940 560 mg</intervention_name>
    <description>Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous</description>
    <arm_group_label>560/320/320 mg of UCB4940</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical Form: solution
Concentration: 0.9 % sodium chloride
Route of Administration: intravenous</description>
    <arm_group_label>240/160/160 mg of UCB4940</arm_group_label>
    <arm_group_label>160/80/80 mg of UCB4940</arm_group_label>
    <arm_group_label>80/40/40 mg of UCB4940</arm_group_label>
    <arm_group_label>560/320/320 mg of UCB4940</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of adult-onset psoriatic arthritis made at least 6 months prior to
             Screening as defined by the Classification Criteria for Psoriatic Arthritis

          -  Subject must have active psoriatic lesions or a history of psoriatic skin lesions

          -  Subject must have active arthritis

          -  Subject has had inadequate response to at least 1 nonbiologic Disease-Modifying
             Antirheumatic Drug (DMARD) (which may include methotrexate [MTX]) and/or 1 approved
             biologic DMARD

          -  Subject must be taking concurrent MTX for at least 3 months at time of Screening, and
             be on a stable dose at least 4 weeks prior to Baseline

          -  Female subject must be postmenopausal (at least 1 year), permanently sterilized or, if
             of childbearing potential, must be willing to use at least 2 effective methods of
             contraception during the study period

          -  Subject has clinical laboratory test results within the reference ranges of the
             testing laboratory

          -  Subject has Electrocardiogram (ECG) values within the reference ranges of the testing
             laboratory

        Exclusion Criteria:

          -  Subject has absolute neutrophil count &lt;1.5×109/L, and/or lymphocyte count &lt;1.0×109/L

          -  Subject has known viral hepatitis, has a positive test for hepatitis B surface antigen
             or is hepatitis C virus antibody positive

          -  Subject tests positive to human immunodeficiency virus (HIV)-1/2 antibody

          -  Subject has a past medical history or family history of primary immunodeficiency

          -  Subject is splenectomized

          -  Subject has had a severe infection requiring hospitalization and/or treatment with iv
             antibiotics in the 6 months before the Screening Visit

          -  Subject has a history of positive tuberculosis (TB) test or evidence of possible TB or
             latent TB infection at Screening

          -  Subject has a high risk of acquiring TB infection

          -  Subject has a history of alcoholism or drug/chemical abuse

          -  Subject has an active infection or has had a serious within 6 weeks before the first
             dose of Investigational Medicinal Product (IMP)

          -  Subject has renal or liver impairment at the Screening Visit

          -  Subject has active neoplastic disease or history of neoplastic disease within 5 years
             of study entry (except for basal or squamous cell carcinoma of the skin or carcinoma
             in situ which has been definitively treated with standard of care approaches and is
             considered cured at Screening)

          -  Subject has any other acute or chronic illness which, in the opinion of the
             Investigator or Study Physician, could pose a threat or harm to the subject

          -  Subjects must not have a diagnosis of any other inflammatory arthritis, eg, rheumatoid
             arthritis, sarcoidosis, or systemic lupus erythematosus

          -  Subject has a current or past history of gastrointestinal ulceration

          -  Subjects must not have a noninflammatory condition (eg, osteoarthritis or a known
             diagnosis of fibromyalgia) that in the Investigator's opinion is symptomatic enough to
             interfere with evaluation of the effect of IMP on the subject's primary diagnosis of
             Psoriatic Arthritis (PsA)

          -  Subject has received a live vaccination within 6 weeks before the Screening Visit or
             intends to have or will need a live vaccination during the course of the study or for
             the 3 months following last IMP dosing

          -  Subject has had an inadequate response to more than 1 approved biologic Drug-Modifying
             Antirheumatic Drug (DMARD)

          -  Subject has received any investigational drug or experimental procedure within 90 days
             or 5 half-lives whichever is the longer before the first dose of UCB4940
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>001</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>002</name>
      <address>
        <city>St. Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>003</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Moldova, Republic of</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2014</study_first_submitted>
  <study_first_submitted_qc>May 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2014</study_first_posted>
  <last_update_submitted>August 31, 2015</last_update_submitted>
  <last_update_submitted_qc>August 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriatic Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

